ERBB2 and cancer: PDOs #30 were obtained from a tumor classified as HER2-enriched, but IHC and WES analyses of these PDOs revealed that the derived organoid line was HER2 negative, raising the possibility that it originated from a HER2 negative cancer cell subpopulation of the parental tumor.